Kiora Pharmaceuticals has added a second clinical-stage drug to its pipeline, licensing global rights to a treatment for a rare condition that can cause sudden, permanent vision loss.
The Encinitas-based retinal therapeutics company, traded on Nasdaq under the ticker KPRX, signed an exclusive license agreement Oct. 23 with Osaka, Japan-based Senju Pharmaceutical Co. for KIO-401, according to a company press release and an SEC filing. The deal covers development and commercialization rights outside Asia for the oral drug candidate, which the company describes as targeting central retinal artery occlusion (CRAO), a "stroke of the eye."
CRAO strikes without warning. Kiora President and CEO Brian Strem described the condition as an emergency in which patients lose nearly all vision in one eye suddenly and painlessly, with only minimal recovery afterward, in an interview with the San Diego Business Journal.
No approved therapies exist for CRAO in the United States, according to the company. An estimated 6,500 to 7,000 cases are reported in the U.S. each year, Strem told the San Diego Business Journal.
Under the agreement, Kiora will pay Senju $3.5 million upfront, according to the SEC filing. Kiora will also pay a technology transfer milestone in the low teen millions of dollars, plus up to $168.5 million tied to regulatory and commercial milestones. Senju will receive single-digit royalties on net sales outside Asia.
Senju has already completed Phase 2 and Phase 3 clinical studies of KIO-401 in Japan. The drug showed meaningful visual acuity improvement compared to controls in those trials, according to the press release. Kiora plans to launch a multinational Phase 3 registration study in 2027, with enrollment expected to exceed 100 patients across the U.S., parts of Europe and other countries.
The company is still finalizing details including sample size, primary endpoint and enrollment criteria for that trial, the San Diego Business Journal reported.
KIO-401 works by blocking an enzyme called calpain that becomes overactive when oxygen delivery to the retina is cut off. That overactivation damages cells in the eye and leads to vision loss. The goal, Strem told the San Diego Business Journal, is to "keep those cells alive" long enough for the body's own blood-flow restoration to kick in.
Kiora also plans to test KIO-401 in a Phase 2b trial for non-arteritic anterior ischemic optic neuropathy (NAION), a similar rare condition that affects about 10,000 to 12,000 Americans annually and also has no approved U.S. treatment. That trial is targeted to begin in 2028, pending funding and regulatory details.
The roughly 20-employee company, headquartered at 169 Saxony Road in Encinitas, rebranded from EyeGate Pharmaceuticals in 2021 after its previous lead drug failed Phase 3 trials in 2018. Strem has led the company since the rebrand.
Kiora's existing lead candidate, KIO-301, treats inherited retinal diseases like retinitis pigmentosa. The company struck a partnership for that drug in 2024 with Théa Open Innovation, a sister company of French ophthalmic firm Laboratoires Théa, valued at up to $301 million. A separate deal gave Senju rights to KIO-301 in Asian markets outside South Korea.
That existing Senju relationship led to the KIO-401 license, Strem said. Kiora reported $17.1 million in cash on hand, according to the San Diego Business Journal.



